- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Paul Billings Discusses the Financial Burden of Prescription Drug Costs in Medicare
Unlike commercial plans, Medicare beneficiaries run the risk hitting the donut hole, which causes their costs to go up dramatically, said Paul Billings, senior vice president advocacy for the American Lung Association.
Unlike commercial plans, Medicare beneficiaries run the risk hitting the donut hole, which causes their costs to go up dramatically, said Paul Billings, senior vice president advocacy for the American Lung Association.
Transcript
How does the financial burden of high prescription drug costs among the Medicare population differ from the non-Medicare population?
So, Medicare’s prescription drug benefit is designed differently than many private health plans, and what we see is that patients hit what is known as the donut hole, where their costs go up dramatically through their plan year, and that leads to patients having to face much higher costs when they show up at the pharmacy counter.
We had an experience with a patient that was used to paying $42 for each prescription, and she showed up and it was $175. It was quite a shock to her and she couldn’t afford it. So, patients experience these high costs and all of a sudden it can impact their ability to afford medication, and if they can’t afford their medication, it can lead to a wide range of additional health burdens. People with chronic obstructive pulmonary disease can end up hospitalized when they’ve had an exacerbation, rather than maintaining good health or managing their disease by being able to adhere to their medications.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
